Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …

Pulmonary embolism (PE) is the leading cause of in-hospital death and the third most
frequent cause of cardiovascular death. The clinical presentation of PE is variable, and …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable form of pulmonary
hypertension and right heart failure. CTEPH (group 4 pulmonary hypertension) is caused by …

Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to
pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in …

Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients
with chronic thromboembolic pulmonary disease with and without pulmonary hypertension …

Background Cardiopulmonary exercise testing (CPET) may provide prognostically valuable
information during follow-up after pulmonary embolism (PE). Our objective was to …

Background As mortality from pulmonary embolism (PE) decreases, the personal and
societal costs among survivors are receiving increasing attention. Detailing this burden …

The complete picture of the outcomes of venous thromboembolism (VTE) care consists of
conventional binary clinical outcomes (death, recurrent VTE, and bleeding), patient-centered …

Background Diagnostic rates and risk factors for the subsequent development of chronic
thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism (PE) are …